Specifications
Properties
Additional Info
Background
Specifications
| SPECIES REACTIVITY: | Human |
|---|---|
| HOMOLOGY: | Predicted species reactivity based on immunogen sequence: Rabbit: (75%), Mouse: (75%) |
| TESTED APPLICATIONS: | ELISA, IF, IHC-P, WB |
| APPLICATIONS: | CD86 antibody can be used for Western blot at 1 - 2 μg/mL. Antibody can also be used for Immunohistochemistry at 2 μg/mL. For Immunoflorescence start at 20 μg/mL. |
| USER NOTE: | Optimal dilutions for each application to be determined by the researcher. |
| POSITIVE CONTROL: | 1) Cat. No. 1224 - Daudi Cell Lysate |
| 2) Cat. No. 1207 - Raji Cell Lysate | |
| PREDICTED MOLECULAR WEIGHT: | Predicted: 36 kDa Observed: 68 kDa |
| SPECIFICITY: | At least five isoforms of CD86 are known to exist; this antibody will detect all five isoforms. |
| IMMUNOGEN: | CD86 antibody was raised against a peptide corresponding to 17 amino acids near the center of human CD86. The immunogen is located within amino acids 160 - 210 of CD86. |
| HOST SPECIES: | Rabbit |
Properties
| PURIFICATION: | CD86 Antibody is affinity chromatography purified via peptide column. |
|---|---|
| PHYSICAL STATE: | Liquid |
| BUFFER: | CD86 Antibody is supplied in PBS containing 0.02% sodium azide. |
| CONCENTRATION: | 1 mg/mL |
| STORAGE CONDITIONS: | CD86 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| CLONALITY: | Polyclonal |
| ISOTYPE: | IgG |
| CONJUGATE: | Unconjugated |
Additional Info
| ALTERNATE NAMES: | CD86 Antibody: CD86 molecule, B70, B7-2, B7.2, LAB72, CD28LG2 |
|---|---|
| ACCESSION NO.: | NP_787058 |
| PROTEIN GI NO.: | 332634934 |
| OFFICIAL SYMBOL: | CD86 |
| GENE ID: | 942 |
Background
| BACKGROUND: | CD86, also known as B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD80, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|---|---|
| REFERENCES: | 1) Lane P. Regulation of T and B cell responses by modulating interactions between CD28/CTLA-4 and their ligands, CD80 and CD86. Ann NY Acad Sci 1997; 815:392-400. | 2) Feucht J, Kayser S, Gorodezki D, et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 2016; 7:76902-19. |
For Research Use Only
